Your browser doesn't support javascript.
loading
2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K.
Li, Er-Dong; Lin, Qiao; Meng, Ya-Qi; Zhang, Lu-Ye; Song, Pan-Pan; Li, Na; Xin, Jing-Chao; Yang, Peng; Bao, Chong-Nan; Zhang, Dan-Qing; Zhang, Yang; Wang, Ji-Kuan; Zhang, Qiu-Rong; Liu, Hong-Min.
Afiliación
  • Li ED; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Lin Q; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Meng YQ; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Zhang LY; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Song PP; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Li N; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Xin JC; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Yang P; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Bao CN; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Zhang DQ; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Zhang Y; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Wang JK; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China.
  • Zhang QR; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China. Electronic address: zqr409@yeah.net.
  • Liu HM; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450001, PR China. Electronic address: liuhm@zzu.edu.cn.
Eur J Med Chem ; 172: 36-47, 2019 Jun 15.
Article en En | MEDLINE | ID: mdl-30939352
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Quinazolinas / Neoplasias de la Mama / Fosfatidilinositol 3-Quinasas / Inhibidores de Proteínas Quinasas / Antineoplásicos Límite: Female / Humans Idioma: En Revista: Eur J Med Chem Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Quinazolinas / Neoplasias de la Mama / Fosfatidilinositol 3-Quinasas / Inhibidores de Proteínas Quinasas / Antineoplásicos Límite: Female / Humans Idioma: En Revista: Eur J Med Chem Año: 2019 Tipo del documento: Article